EMVision Medical Devices has received a $4.3 million R&D tax refund, adding non-dilutive funding as it progresses clinical work on its emu™ and First Responder devices. The cash arrives against a last reported cash balance of $17.1 million and $4.6 million in remaining grant funding at 30 June 2026.
- $4.3 million R&D tax refund received for FY2026 activities
- Non-dilutive funding supports clinical, engineering and product development
- emu™ pivotal trial spans leading US and Australian stroke centres
- First Responder program completes aeromedical and in-field feasibility work
- FY2027 activities expected to remain eligible for the incentive
$4.3 Million Refund Adds Development Funding
EMVision Medical Devices Limited (ASX:EMV) has received a $4.3 million cash refund under the Australian Government’s R&D Tax Incentive, giving the medical device developer additional non-dilutive funding at a critical stage of its clinical and product programs.
The refund relates to eligible research and development activities undertaken during the year ended 30 June 2026. EMVision’s last reported cash position was $17.1 million, with a further $4.6 million in remaining grant funding as at that date. Those figures predate the refund, and the announcement does not provide an updated post-refund cash balance.
emu™ Trial Anchors FY2026 Research
The eligible work included the emu™ Pivotal, or Validation, Trial, which is intended to support a future US Food and Drug Administration clearance process. Recruitment has involved Mayo Clinic, UCLA, Memorial Hermann, Mount Sinai, Royal Melbourne Hospital, Liverpool Hospital and Princess Alexandra Hospital.
The refund also covers eligible overseas expenditure associated with the emu™ trial and related market access activities under EMVision’s Advance Overseas Finding. That treatment matters because the company’s development program is being conducted across both Australian and US clinical settings, rather than being confined to domestic research expenditure.
First Responder Program Completes Feasibility Work
EMVision said FY2026 was its most active development year to date, with eligible activities spanning clinical, engineering and product development work for both the emu™ and First Responder devices. The First Responder program has completed aeromedical and in-field feasibility and usability studies, according to the announcement.
The funding is supportive rather than conclusive: receiving the tax refund does not establish that either device will achieve the clinical outcomes, regulatory approvals or commercial success required for a viable product. EMVision expects to continue accessing the incentive for eligible FY2027 activities, leaving future cash support partly linked to the scale and nature of qualifying research expenditure.
Bottom Line?
The refund improves EMVision’s funding runway, but the next value-moving evidence remains clinical progress, FDA-related milestones and the company’s updated cash position.
Questions in the middle?
- How much of the post-refund funding will be directed to the emu™ pivotal trial and FDA submission work?
- When will EMVision report an updated cash balance incorporating the $4.3 million receipt?
- Can the First Responder feasibility results translate into the regulatory and commercial milestones still ahead?